Katerina A. Politi, Ph.D. - Publications

Affiliations: 
2003 Columbia University, New York, NY 
Area:
Genetics, Oncology, Molecular Biology

121 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, et al. Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nature Communications. 13: 4640. PMID 35941179 DOI: 10.1038/s41467-022-32459-x  0.351
2022 Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35713632 DOI: 10.1158/1078-0432.CCR-22-0741  0.343
2022 Foggetti G, Li C, Cai H, Petrov DA, Winslow MM, Politi K. Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment. Molecular & Cellular Oncology. 9: 1994328. PMID 35252550 DOI: 10.1080/23723556.2021.1994328  0.452
2022 Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, et al. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. Jci Insight. 7. PMID 35132961 DOI: 10.1172/jci.insight.142843  0.381
2022 Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma. Npj Precision Oncology. 6: 8. PMID 35087143 DOI: 10.1038/s41698-021-00248-2  0.337
2021 Tripathi BK, Anderman MF, Bhargava D, Boccuzzi L, Qian X, Wang D, Durkin ME, Papageorge AG, de Miguel FJ, Politi K, Walters KJ, Doroshow JH, Lowy DR. Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein. Nature Communications. 12: 6941. PMID 34862367 DOI: 10.1038/s41467-021-26993-3  0.317
2021 Arnal-Estapé A, Foggetti G, Starrett JH, Nguyen DX, Politi K. Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Cold Spring Harbor Perspectives in Medicine. PMID 34518338 DOI: 10.1101/cshperspect.a037820  0.355
2021 Robles-Oteiza C, Ayeni D, Levy S, Homer RJ, Kaech SM, Politi K. Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma. Disease Models & Mechanisms. PMID 34494649 DOI: 10.1242/dmm.049072  0.467
2021 Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini DG, Rashleigh N, Levy S, Homer R, Gettinger SN, ... ... Politi K, et al. Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discovery. PMID 33707235 DOI: 10.1158/2159-8290.CD-20-1385  0.522
2020 Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, et al. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001149. PMID 33021871 DOI: 10.1200/JCO.20.01149  0.465
2020 Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech S, ... ... Politi K, et al. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Research. PMID 32193290 DOI: 10.1158/0008-5472.Can-19-3819  0.567
2020 Cardenas JJ, Robles-Oteiza C, Politi K. Assessment of IFNγ responsiveness in patient-derived xenografts. Methods in Enzymology. 631: 415-427. PMID 31948560 DOI: 10.1016/Bs.Mie.2019.10.027  0.412
2020 Mack PC, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MAC, Walther Z, Hirsch FR, Politi KA, Kelly K, Gandara DR. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal of Clinical Oncology. 38: 9532-9532. DOI: 10.1200/Jco.2020.38.15_Suppl.9532  0.453
2020 Cai H, Li C, Chew SK, Yousefi M, Foggetti G, Lin W, Rogers ZN, Winters IP, McFarland CD, Politi K, Swanton C, Petrov DA, Winslow MM. Abstract IA26: Multiplexed functional cancer genomics Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Ia26  0.342
2020 Politi KA. Abstract IA10: Modeling sensitivity and resistance to systemic therapies in lung cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Ia10  0.621
2020 Hu B, Miguel FJd, Liu Z, Chan L, Melnick MA, Yan Q, Nguyen D, Fan R, Politi K. Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A13  0.588
2020 Foggetti G, Li C, Cai H, Lin W, Ayeni D, Hastings K, Andrejka L, Maghini D, Homer R, Petrov DA, Winslow MM, Politi K. Abstract 1094: Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo Cancer Research. 80: 1094-1094. DOI: 10.1158/1538-7445.Am2020-1094  0.618
2020 Starrett JH, Guernet A, Cuomo ME, Poels K, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, ... ... Politi K, et al. Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00612  0.443
2020 Starrett J, Guernet A, Cuomo M, Poels K, van Alderwerelt van Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, ... ... Politi K, et al. B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations Journal of Thoracic Oncology. 15: S36. DOI: 10.1016/J.Jtho.2019.12.097  0.426
2020 de Miguel F, Hu B, Cai W, Sun N, Melnick M, Nguyen D, Xiao A, Politi K. B30 The Role of SMARCA4 as an EGFR-Independent Mechanism of Resistance to Osimertinib Journal of Thoracic Oncology. 15: S35-S36. DOI: 10.1016/J.Jtho.2019.12.095  0.396
2020 Politi K. IA31 Genetic Contributors to Tumor Progression and Drug Resistance in EGFR Mutant Lung Cancer Journal of Thoracic Oncology. 15: S10. DOI: 10.1016/j.jtho.2019.12.029  0.469
2019 Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. Journal For Immunotherapy of Cancer. 7: 221. PMID 31416487 DOI: 10.1186/S40425-019-0683-0  0.338
2019 Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, ... ... Politi K, et al. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. Journal For Immunotherapy of Cancer. 7: 172. PMID 31291990 DOI: 10.1186/S40425-019-0643-8  0.584
2019 Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31182434 DOI: 10.1158/1078-0432.Ccr-19-0780  0.538
2019 Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, ... ... Politi K, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 131. PMID 31113486 DOI: 10.1186/S40425-019-0602-4  0.35
2019 Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, ... ... Politi K, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31086949 DOI: 10.1093/Annonc/Mdz141  0.551
2019 Datar IJ, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki MI, Mejías L, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, ... ... Politi K, et al. Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31053602 DOI: 10.1158/1078-0432.Ccr-18-4142  0.439
2019 Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. Cell Reports. 27: 1277-1292.e7. PMID 31018140 DOI: 10.1016/J.Celrep.2019.03.085  0.313
2019 Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30824587 DOI: 10.1158/1078-0432.Ccr-18-1538  0.449
2018 Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications. 9: 3196. PMID 30097571 DOI: 10.1038/S41467-018-05032-8  0.415
2018 Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, ... ... Politi K, et al. amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. PMID 29875142 DOI: 10.1073/Pnas.1717782115  0.643
2018 Wilson FH, Politi K. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discovery. 8: 676-678. PMID 29858224 DOI: 10.1158/2159-8290.Cd-18-0368  0.432
2018 Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, ... ... Politi K, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nature Medicine. PMID 29686424 DOI: 10.1038/S41591-018-0007-9  0.568
2018 Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29578107 DOI: 10.1016/J.Jtho.2018.03.008  0.435
2018 Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29330207 DOI: 10.1158/1078-0432.Ccr-17-1341  0.485
2018 Stewart T, Truini A, DeVeaux M, Zelterman D, Walther Z, Wurtz A, Gettinger SN, Politi KA, Goldberg SB. Differential outcomes in patients with uncommon EGFR exon 19 mutations. Journal of Clinical Oncology. 36: 9056-9056. DOI: 10.1200/Jco.2018.36.15_Suppl.9056  0.416
2018 Hastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, ... ... Politi K, et al. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A09  0.501
2018 Goldberg S, Redman M, Lilenbaum R, Politi K, Stinchcombe T, Horn L, Chen E, Mashru S, Gettinger S, Melnick MA, Miao J, Moon J, Kelly K, Gandara D. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403 Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.290  0.496
2017 Aisner DL, Sholl LM, Berry L, Rossi M, Chen H, Fujimoto J, Moreira AL, Ramalingam S, Villaruz LC, Otterson GA, Haura EB, Politi K, Glisson BS, Cetnar J, Garon E, et al. The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29217530 DOI: 10.1158/1078-0432.Ccr-17-2289  0.532
2017 Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. Biomed Research International. 2017: 7694202. PMID 29119113 DOI: 10.1155/2017/7694202  0.524
2017 Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, ... ... Politi K, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery. PMID 29025772 DOI: 10.1158/2159-8290.Cd-17-0593  0.479
2017 Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer (Amsterdam, Netherlands). 109: 1-8. PMID 28577937 DOI: 10.1016/J.Lungcan.2017.04.010  0.477
2017 Henick BS, Goldberg SB, Narayan A, Rossi C, Rodney S, Kole AJ, Politi KA, Gettinger SN, Herbst RS, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: e20652-e20652. DOI: 10.1200/Jco.2017.35.15_Suppl.E20652  0.503
2017 Datar I, Mani N, Henick BS, Wurtz A, Kaftan E, Herbst RS, Rimm DL, Gettinger SN, Politi KA, Schalper KA. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E14611  0.368
2017 Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, Germer S, Jordan E, Wang L, Jungbluth AA, Spraggon L, Lovly CM, Kris MG, Yu HA, Riely GJ, ... ... Politi KA, et al. YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. Journal of Clinical Oncology. 35: 9043-9043. DOI: 10.1200/Jco.2017.35.15_Suppl.9043  0.643
2017 Goldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N, Lee A, Nemati R, Nath S, Mane S, Deng Y, Sukumar N, Zelterman D, Boffa D, Politi K, et al. Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA Annals of Oncology. 28: v478. DOI: 10.1093/Annonc/Mdx380.043  0.467
2017 Elamin Y, Robichaux J, Lam V, Tsao A, Lu C, Blumenschein G, Kurie J, Brahmer J, Li S, Chen T, Estrada-Bernal A, Truini A, Nilsson M, Le A, Tan Z, ... ... Politi K, et al. OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC Journal of Thoracic Oncology. 12: S1776. DOI: 10.1016/J.Jtho.2017.09.394  0.454
2017 Kris M, Aisner D, Sholl L, Berry L, Rossi M, Chen H, Fujimoto J, Moreira A, Ramalingam S, Villaruz L, Otterson G, Haura E, Politi K, Glisson B, Cetnar J, et al. P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor Journal of Thoracic Oncology. 12: S2275. DOI: 10.1016/J.Jtho.2017.09.1633  0.467
2017 Mack P, Miao J, Banks K, Burich R, Politi K, Raymond V, Dix D, Lanman R, Moon J, Melnick MA, Truini A, Redman M, Goldberg S, Gandara DR, Kelly K. P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1487  0.395
2017 Hastings K, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Zhao Z, Gaffney S, Iamarino A, Zhao S, Bi M, Goldberg S, Chiang A, Liu Z, Townsend J, ... ... Politi K, et al. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas Journal of Thoracic Oncology. 12: S435. DOI: 10.1016/J.Jtho.2016.11.507  0.544
2017 Suda K, Rozeboom L, Rivard C, Yu H, Melnick MA, Hinz T, Ellison K, Chan D, Politi K, Heasley L, Mitsudomi T, Hirsch FR. MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer Journal of Thoracic Oncology. 12: S433-S434. DOI: 10.1016/J.Jtho.2016.11.505  0.498
2017 Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S430-S431. DOI: 10.1016/J.Jtho.2016.11.501  0.499
2017 Choi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick MA, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, ... ... Politi K, et al. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S1331-S1332. DOI: 10.1016/J.Jtho.2016.11.1884  0.456
2017 Goldberg S, Moon J, Lilenbaum R, Politi K, Melnick MA, Stinchcombe T, Horn L, Chen E, Miao J, Redman M, Kelly K, Gandara DR. P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403: Topic: EGFR Clinical Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1719  0.434
2016 McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, et al. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 27702896 DOI: 10.1073/Pnas.1613601113  0.738
2016 Gettinger S, Politi K. PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? Clinical Cancer Research. 22: 4539-4541. PMID 27470969 DOI: 10.1158/1078-0432.Ccr-16-1401  0.474
2016 Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, et al. Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports. PMID 27346347 DOI: 10.1016/J.Celrep.2016.05.087  0.564
2016 Xia B, Wurtz A, Gettinger SN, Herbst RS, Chiang AC, Wan M, Sklar J, Neumeister V, Politi KA, Goldberg SB. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal of Clinical Oncology. 34: 9049-9049. DOI: 10.1200/Jco.2016.34.15_Suppl.9049  0.512
2016 Aisner D, Sholl LM, Berry LD, Haura EB, Ramalingam SS, Glisson BS, Socinski MA, Waqar SN, Garon EB, Cetnar JP, Politi KA, Schiller J, Rossi MR, Chen H, Minna JD, et al. Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. Journal of Clinical Oncology. 34: 11510-11510. DOI: 10.1200/Jco.2016.34.15_Suppl.11510  0.469
2016 Ayeni D, Ho P, Perry C, Kaech S, Politi K. Abstract A083: Modulation of the immune system as a strategy to treat EGFR mutant lung adenocarcinoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A083  0.554
2016 Raad RA, Walther Z, Gettinger S, Politi K, Puchalski J, Homer R, Cai G. Tumor Genotyping Analysis Using Cytological Specimens of Primary and Metastatic Lung Adenocarcinomas Journal of the American Society of Cytopathology. 5. DOI: 10.1016/J.Jasc.2016.07.122  0.459
2015 Pirazzoli V, Ayeni D, Meador CB, Sanganahalli B, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26341921 DOI: 10.1158/1078-0432.Ccr-15-0620  0.545
2015 Morgensztern D, Politi K, Herbst RS. EGFR Mutations in Non-Small-Cell Lung Cancer Find, Divide, and Conquer Jama Oncology. 1: 146-148. PMID 26181013 DOI: 10.1001/Jamaoncol.2014.278  0.543
2015 Ayeni D, Politi K, Goldberg SB. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26169963 DOI: 10.1158/1078-0432.Ccr-15-1211  0.542
2015 Politi K, Ayeni D, Lynch T. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell. 27: 751-3. PMID 26058074 DOI: 10.1016/J.Ccell.2015.05.012  0.547
2015 Politi K, Herbst RS. Lung Cancer in the Era of Precision Medicine Clinical Cancer Research. 21: 2213-2220. PMID 25979927 DOI: 10.1158/1078-0432.Ccr-14-2748  0.536
2015 Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, et al. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discovery. 5: 534-49. PMID 25735773 DOI: 10.1158/2159-8290.CD-14-0750  0.656
2015 Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas. Cancer Research. 75: 1035-45. PMID 25596284 DOI: 10.1158/0008-5472.Can-13-1625  0.685
2015 Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Molecular Cancer Therapeutics. 14: 542-52. PMID 25477325 DOI: 10.1158/1535-7163.Mct-14-0723  0.545
2015 Bantikassegn A, Song X, Politi K. Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas. American Journal of Respiratory Cell and Molecular Biology. 52: 409-17. PMID 25347711 DOI: 10.1165/Rcmb.2014-0312Ma  0.468
2015 Kris MG, Johnson BE, Kwiatkowski DJ, Wistuba II, Berry LD, Haura EB, Socinski MA, Ramalingam SS, Glisson BS, Waqar SN, Otterson GA, Schiller JH, Garon EB, Cetnar JP, Politi KA, et al. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). Journal of Clinical Oncology. 33: 8094-8094. DOI: 10.1200/Jco.2015.33.15_Suppl.8094  0.543
2014 Politi K, Gettinger S. Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer Clinical Cancer Research. 20: 5576-5578. PMID 25228532 DOI: 10.1158/1078-0432.Ccr-14-2306  0.57
2014 Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, ... ... Politi K, et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports. 7: 999-1008. PMID 24813888 DOI: 10.1016/J.Celrep.2014.04.014  0.497
2014 de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, ... ... Politi K, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discovery. 4: 606-19. PMID 24535670 DOI: 10.1158/2159-8290.Cd-13-0741  0.696
2014 Lockwood W, Politi K. MYCxing it up with FGFR1 in squamous cell lung cancer. Cancer Discovery. 4: 152-154. PMID 24501305 DOI: 10.1158/2159-8290.Cd-13-1049  0.479
2014 Pirazzoli V, Politi K. Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse. Csh Protocols. 2014: 178. PMID 24492774 DOI: 10.1101/Pdb.Prot077842  0.455
2014 Olive KP, Politi K. Translational Therapeutics in Genetically Engineered Mouse Models of Cancer Csh Protocols. 2014: 131-143. PMID 24492770 DOI: 10.1101/Pdb.Top069997  0.358
2014 Goldberg SB, Narayan A, Carriero NJ, Nemati R, Bommakanti A, Wurtz A, Boffa DJ, Decker RH, Herbst RS, Juergensmeier JM, Politi KA, Gettinger SN, Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma. Journal of Clinical Oncology. 32: 8093-8093. DOI: 10.1200/Jco.2014.32.15_Suppl.8093  0.558
2013 Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP. DOK2 inhibits EGFR-mutated lung adenocarcinoma. Plos One. 8: e79526. PMID 24255704 DOI: 10.1371/Journal.Pone.0079526  0.686
2013 Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/Gr.152322.112  0.513
2013 Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discovery. 3: 168-81. PMID 23229345 DOI: 10.1158/2159-8290.Cd-12-0357  0.53
2013 Lee H, Schaefer G, Heffron T, Malek S, Merchant M, Yauch RL, Pirazzoli V, Politi K, Settleman J. Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M . Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-309  0.542
2013 Pirazzoli V, Stanchina Ed, Xia J, Zhao Z, Pao W, Politi KA. Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer. Cancer Research. 73: 933-933. DOI: 10.1158/1538-7445.Am2013-933  0.604
2013 Pirazzoli V, Nebhan C, Song X, Walter Z, Cai G, Wurtz A, Zhao Z, Stanchina EEd, Horn L, Carbone D, Stevens PJ, Miller V, Gettinger S, Pao W, Politi K. Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C90  0.617
2013 Song X, Fan P, Guha U, Threadgill D, Varmus H, Politi K. Abstract C113: ERBB3 independent activation of the PI3K pathway in EGFR mutant lung adenocarcinomas. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C113  0.702
2012 Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. 2: 922-33. PMID 22956644 DOI: 10.1158/2159-8290.Cd-12-0108  0.597
2012 Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, ... ... Politi K, et al. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. The Journal of Clinical Investigation. 122: 2637-51. PMID 22653055 DOI: 10.1172/Jci62058  0.519
2012 Politi K, Lynch TJ. Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1490-2. PMID 22317760 DOI: 10.1158/1078-0432.Ccr-11-3282  0.559
2012 Ohashi K, Chmielecki J, Lin Y, Pan H, Vnencak-Jones C, Arcila M, Wang L, Fernandez L, Keisuke A, Shien K, Yamamoto H, Toyooka S, Kiura K, Thomas R, Yang JC, ... ... Politi K, et al. Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer Cancer Research. 72: 1897-1897. DOI: 10.1158/1538-7445.Am2012-1897  0.599
2012 Sangodkar J, Dhawan N, Melville H, Singh VJ, Farrington C, Yuan E, Rana H, Smith B, Gidwani V, Okrent R, Burstein D, Ohlmeyer M, Politi K, DiFeo A, Narla G. Abstract 1885: Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy Cancer Research. 72: 1885-1885. DOI: 10.1158/1538-7445.Am2012-1885  0.554
2012 Pirazzoli V, Takezawa K, de Stanchina E, Pao W, Politi K. Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas Clinical Cancer Research. 18: A38-A38. DOI: 10.1158/1078-0432.Mechres-A38  0.567
2012 Takezawa K, Melnick MA, Riely G, Kris M, Miller V, Ladanyi M, Politi K, Pao W, Pirazzoli V, Song X, Arcila M, De Stanchina E, Ohashi K, Janjigian Y, Spitzler P, et al. Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer Clinical Cancer Research. 18: A23-A23. DOI: 10.1158/1078-0432.Mechres-A23  0.592
2012 Bruin Ed, Cowell C, Howell M, Varmus H, Politi K, Downward J. Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-A18  0.679
2012 Politi KA. Abstract IA4: Defining the mechanisms of tumorigenesis by mutant EGFR using mouse models Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.12Aacriaslc-Ia4  0.615
2012 Song X, Fan P, Guha U, Threadgill D, Varmus H, Politi K. Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR-driven Lung Cancer Clinical Cancer Research. 18: B35-B35. DOI: 10.1158/1078-0432.12Aacriaslc-B35  0.678
2011 Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 20: 289-99. PMID 21907921 DOI: 10.1016/J.Ccr.2011.08.007  0.615
2011 Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2273-81. PMID 21263096 DOI: 10.1200/Jco.2010.30.8304  0.39
2011 Bruin ECd, Cowell CF, Howell M, Varmus HE, Politi K, Downward J. Abstract LB-398: Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-398  0.716
2011 Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Sage J, Kemp CJ, Varmus HE, Hanash SM. Abstract 3166: Lung cancer bio-signatures in plasma based on the analysis of mouse models Cancer Research. 71: 3166-3166. DOI: 10.1158/1538-7445.Am2011-3166  0.601
2010 Politi K, Fan PD, Shen R, Zakowski M, Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Disease Models & Mechanisms. 3: 111-9. PMID 20007486 DOI: 10.1242/Dmm.003681  0.697
2010 McFadden DG, Xuan Z, Rosebrock A, Politi K, Santiago P, Hodges E, Winslow M, Hiramatsu N, Pirun M, Crowley D, Bronson R, Socci N, Varmus H, Hannon G, Jacks T. Abstract LB-151: Targeted gene resequencing in a K-ras-dependent mouse model of metastatic lung adenocarcinoma Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-151  0.71
2010 Sangodkar J, Katz S, Albano T, Melville H, Burstein D, Politi K, Difeo A, Narla G. Abstract B41: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B41  0.572
2009 Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/Pnas.0907325106  0.482
2009 Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. The Journal of Clinical Investigation. 119: 3000-10. PMID 19759520 DOI: 10.1172/Jci38746  0.617
2008 Zhang Q, Menon R, Deutsch EW, Pitteri SJ, Faca VM, Wang H, Newcomb LF, Depinho RA, Bardeesy N, Dinulescu D, Hung KE, Kucherlapati R, Jacks T, Politi K, Aebersold R, et al. A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biology. 9: R93. PMID 18522751 DOI: 10.1186/Gb-2008-9-6-R93  0.442
2008 Podsypanina K, Politi K, Beverly LJ, Varmus HE. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proceedings of the National Academy of Sciences of the United States of America. 105: 5242-7. PMID 18356293 DOI: 10.1073/Pnas.0801197105  0.602
2007 Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Plos Medicine. 4: e294. PMID 17927446 DOI: 10.1371/Journal.Pmed.0040294  0.564
2007 Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. Plos One. 2: e810. PMID 17726540 DOI: 10.1371/Journal.Pone.0000810  0.604
2006 Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Wong KK, Kim K. BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: S2-7. PMID 17409996  0.315
2006 Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7232-41. PMID 17189394 DOI: 10.1158/1078-0432.Ccr-06-0658  0.531
2006 Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America. 103: 9262-7. PMID 16751266 DOI: 10.1073/Pnas.0603371103  0.612
2006 Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes & Development. 20: 1496-510. PMID 16705038 DOI: 10.1101/Gad.1417406  0.703
2006 Christiani DC, Pao W, DeMartini JC, Linnoila RI, Malkinson AM, Onn A, Politi KA, Sharp M, Kim K. BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models Journal of Thoracic Oncology. 1: S2-S7. DOI: 10.1016/S1556-0864(15)30002-2  0.408
2005 Varmus H, Pao W, Politi K, Podsypanina K, Du YCN. Oncogenes come of age Cold Spring Harbor Symposia On Quantitative Biology. 70: 1-9. PMID 16869733 DOI: 10.1101/Sqb.2005.70.039  0.599
2005 Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain Plos Medicine. 2: 0225-0235. PMID 15737014 DOI: 10.1371/Journal.Pmed.0020073  0.658
2004 Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 101: 13306-11. PMID 15329413 DOI: 10.1073/Pnas.0405220101  0.692
2004 Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Seminars in Cancer Biology. 14: 341-7. PMID 15288259 DOI: 10.1016/J.Semcancer.2004.04.013  0.37
2004 Kiaris H, Politi K, Grimm LM, Szabolcs M, Fisher P, Efstratiadis A, Artavanis-Tsakonas S. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. The American Journal of Pathology. 165: 695-705. PMID 15277242 DOI: 10.1016/S0002-9440(10)63333-0  0.615
2004 Politi K, Szabolcs M, Fisher P, Kljuic A, Ludwig T, Efstratiadis A. A mouse model of uterine leiomyosarcoma. The American Journal of Pathology. 164: 325-36. PMID 14695345 DOI: 10.1016/S0002-9440(10)63122-7  0.583
2004 Politi K, Kljuic A, Szabolcs M, Fisher P, Ludwig T, Efstratiadis A. 'Designer' tumors in mice. Oncogene. 23: 1558-65. PMID 14661057 DOI: 10.1038/Sj.Onc.1207275  0.627
2002 Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, Morroni M, Cinti S, White MF, Herrera PL, Accili D, Efstratiadis A. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. The Journal of Clinical Investigation. 110: 1011-9. PMID 12370279 DOI: 10.1172/Jci15276  0.557
Show low-probability matches.